Cargando…
The protective effects of liguzinediol on congestive heart failure induced by myocardial infarction and its relative mechanism
BACKGROUND: Heart failure (HF) is one of the most common causes of cardiovascular diseases in the world. Currently, the drugs used to treat HF in the clinic may cause serious side effects. Liguzinediol, 2, 5-dimethyl-3, 6-dimethyl-pyrazine, is a compound synthesized after the structural modification...
Autores principales: | Chen, Qi, Zhang, Dini, Bi, Yunhui, Zhang, Weiwei, Zhang, Yuhan, Meng, Qinghai, Li, Yu, Bian, Huimin |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7296683/ https://www.ncbi.nlm.nih.gov/pubmed/32549908 http://dx.doi.org/10.1186/s13020-020-00345-7 |
Ejemplares similares
-
Synthesis, Biological Evaluation, and Pharmacokinetic Study of Novel Liguzinediol Prodrugs
por: Liu, Zheng, et al.
Publicado: (2013) -
Catalpol Inhibits Macrophage Polarization and Prevents Postmenopausal Atherosclerosis Through Regulating Estrogen Receptor Alpha
por: Chen, Qi, et al.
Publicado: (2021) -
Synthesis and Biological Evaluation of Liguzinediol Mono- and Dual Ester Prodrugs as Promising Inotropic Agents
por: Zhang, Jing, et al.
Publicado: (2014) -
Congestive heart failure
por: Zhao, Xuan
Publicado: (2019) -
Analysis on mechanism of ATP-sensitive K(+) channel opener natakalim improving congestive heart failure after myocardial infarction
por: Jin, Feng
Publicado: (2016)